| Date | Duration | Section |
|---|---|---|
| 2025/04/13 | 00:21 min | Part A |
| 2025/04/13 | 1:30 | Part B |
| 2025/04/21 | :45 | Draw some figures for questions |

<aside> <img src="/icons/slide_green.svg" alt="/icons/slide_green.svg" width="40px" /> Lecture slides will be shared here after the class!
</aside>
<aside> <img src="/icons/video-camera_yellow.svg" alt="/icons/video-camera_yellow.svg" width="40px" /> Class Recording
</aside>
<aside> <img src="/icons/slide_green.svg" alt="/icons/slide_green.svg" width="40px" /> Recitation slides are posted here!
</aside>
<aside> <img src="/icons/video-camera_yellow.svg" alt="/icons/video-camera_yellow.svg" width="40px" /> Recitation Recording
</aside>
<aside> <img src="/icons/exclamation-mark_orange.svg" alt="/icons/exclamation-mark_orange.svg" width="40px" /> These homework questions are based on lecture questions! Mandatory for Committed Listeners.
</aside>
Patrick Boyle’s Lecture Questions:
If I could automate everything that I need to do I think it could open new doors on the projects that I could do the first thing that comes to my mind is the scale of my work will increase meaning I will test and do experiments in a bigger condition so for example when doing a project a research project instead of doing only in silicon and in vitro I would also do something in vivo and maybe even a clinical trial all apps the same project and I think this continuity is very helpful for increasing the integrity and the efficacy of the results meaning you will find your results not only inside the lab but also you will test it in real world scenario and this way the gap between these two sections will be reduced and therefore beware discover science in a better way.
One of the products that I really focus on is maybe during cancer so in a environment that is using automated devices you can iterate and test different experiments very fast and reliably therefore finding solution for some of diseases would be accelerated one area that I'm really excited about is monoclonal antibodies let's say we have a automated machine which is going to build different antibodies against a specific type of cancer and automatically tests and find the result and based on the result it's going to optimize the experiments again to test it again this way I think probability of finding solutions for different diseases would be way more compared to doing a research that isn't going to have that much iteration compared to this

P0.05

Well there are lots of answers for this question ! one interesting area would be creating enzymes that can degrade plastic from ocean and the effect of it will be huge especially if the enzyme is working with a very long half life or let's say it is kind of permanent inside the water and we are essentially using it as system to accelerate degradation of plastic inside ocean
It really depends on what we want and what is our name so for example another cool idea will be creating a Metric ton of a protein which is needed for a disease like cancer I think there are also a great opportunity to use this for eradicating the reason so we can create proteins I guess some disease that are infectious and boy targeting this disease in a high scale manner we might have the opportunity to eradicate the disease entirely.
<aside> <img src="/icons/exclamation-mark_orange.svg" alt="/icons/exclamation-mark_orange.svg" width="40px" /> These homework questions are based on the Bio Production Lab! Mandatory for both Committed Listeners and MIT/Harvard students.
</aside>
<aside> <img src="/icons/push-pin_green.svg" alt="/icons/push-pin_green.svg" width="40px" /> Key Links: http://docs.google.com/document/d/15-tlrejgbbr4FMpA6rKogTjlv6qXJhFqQm7o_Ppfh-I/edit?tab=t.0#heading=h.jyt74412izch
Key Papers:
Based on the text, transferring the genes CrtE, CrtI, and CrtB (from Erwinia herbicola, contained in the pAC-LYC plasmid) into E. coli induces the production of lycopene. To induce beta-carotene production, the gene CrtY (also from Erwinia herbicola) is added along with CrtE, CrtI, and CrtB (these four genes are in the pAC-BETA plasmid).